Pacific Biosciences of California (NASDAQ:PACB) Insider Michele Farmer Sells 35,215 Shares of Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Michele Farmer sold 35,215 shares of Pacific Biosciences of California stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.58, for a total value of $55,639.70. Following the sale, the insider directly owned 234,044 shares in the company, valued at approximately $369,789.52. This trade represents a 13.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michele Farmer also recently made the following trade(s):

• On Wednesday, February 18th, Michele Farmer sold 14,952 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.63, for a total value of $24,371.76.

Pacific Biosciences of California Stock Performance

Shares of NASDAQ:PACB traded down $0.08 during trading on Friday, hitting $1.61. 2,404,905 shares of the stock were exchanged, compared to its average volume of 8,050,623. The company has a market capitalization of $484.57 million, a price-to-earnings ratio of -0.87 and a beta of 2.27. The company has a debt-to-equity ratio of 17.88, a quick ratio of 5.40 and a current ratio of 6.24. Pacific Biosciences of California, Inc. has a 1-year low of $0.85 and a 1-year high of $2.73. The company’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $1.77.

Pacific Biosciences of California (NASDAQ:PACB) last issued its earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07. The firm had revenue of $44.65 million during the quarter, compared to analysts’ expectations of $44.60 million. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%. Sell-side analysts expect that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Ratings Changes

PACB has been the subject of a number of analyst reports. Piper Sandler lifted their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Barclays lifted their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a research note on Thursday, January 22nd. Finally, Stephens boosted their target price on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $2.20.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. ProShare Advisors LLC raised its stake in shares of Pacific Biosciences of California by 10.2% during the fourth quarter. ProShare Advisors LLC now owns 63,799 shares of the biotechnology company’s stock worth $119,000 after buying an additional 5,883 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Pacific Biosciences of California by 5.2% during the third quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 6,564 shares during the period. Mercer Global Advisors Inc. ADV increased its holdings in Pacific Biosciences of California by 47.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 6,695 shares during the last quarter. Rhumbline Advisers lifted its stake in Pacific Biosciences of California by 2.1% in the third quarter. Rhumbline Advisers now owns 415,679 shares of the biotechnology company’s stock valued at $532,000 after buying an additional 8,532 shares during the period. Finally, Green Alpha Advisors LLC boosted its holdings in Pacific Biosciences of California by 5.4% during the fourth quarter. Green Alpha Advisors LLC now owns 183,466 shares of the biotechnology company’s stock worth $343,000 after buying an additional 9,441 shares during the last quarter.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

• Neutral Sentiment: PacBio will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026 — management will do a fireside chat that could provide updated guidance or color on product adoption and commercialization plans. Read More.
• Negative Sentiment: Christian O. Henry sold 331,793 shares on Feb. 17 (avg $1.58) and 140,874 shares on Feb. 18 (avg $1.63) — combined ~472,667 shares for roughly $753,858 in proceeds; each sale reduced his reported ownership (SEC filings). Insider selling at this scale often weighs on sentiment. Read More.
• Negative Sentiment: Oene Mark Van sold 129,790 shares on Feb. 17 (avg $1.58) and 55,107 shares on Feb. 18 (avg $1.63) — total ~184,897 shares (~$294,893). These reductions in his stake were disclosed to the SEC and can pressure the stock. Read More.
• Negative Sentiment: Michele Farmer sold 35,215 shares on Feb. 17 (avg $1.58) and 14,952 shares on Feb. 18 (avg $1.63) — total ~50,167 shares (~$80,011). Her filings show notable reductions in ownership. Read More.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.